Mark S. Soloway, MD

Department Head
Memorial Hospital, Hollywood, FL

Mark S. Soloway, MD. Chief, Urologic Oncology, Memorial Hospital, Hollywood, Fl.
Dr. Soloway is recognized nationally and internationally for his many contributions in the fields of bladder and prostate cancer.
Dr. Soloway has been recognized for his innovative use of case-based teaching to enhance discussion concerning the optimal approach to specific clinical scenarios.
His contributions in BC began when he was a Clinical Associate at the National Cancer Institute. He used an animal model for urothelial carcinoma to identify the efficacy of cisplatin for BC. During his residency he used this model to demonstrate that the high rate of recurrence of urothelial tumors may, in part, be the result of implantation of tumor cells on the injured urothelial surface. This supported the concept of early intravesical chemotherapy.
Dr. Soloway was one of the first to administer cisplatin to bladder cancer patients and report on its efficacy.
Using his mouse model, Dr. Soloway demonstrated the additive effect of radiation and cisplatin for BC. These findings led to clinical trials which confirmed the synergistic effect of radiation plus cisplatin. This remains the principle behind bladder preservation therapy in locally advanced urothelial cancer
Dr. Soloway was the first to highlight the safety of initial active surveillance for low grade Ta bladder tumors.
Dr. Soloway twice chaired an international multidisciplinary committee under the auspices of the SIU and ICUD to develop recommendations on all aspects of urothelial cancer
Dr. Soloway received the Gold Cystoscope Award in 1984. He delivered the Whitmore Memorial Lecture at the Society of Urologic Oncology meeting in 2014. In 2015, he was awarded the St. Paul Medal by BAUS and received the first Lifetime Achievement Award given by the Florida Urological Association. He has published over 550 articles in peer reviewed journals primarily related to prostate, bladder, and kidney cancer.

Disclosure information not submitted.

Presentation(s):

• Case-Based Debate: Is Active Surveillance valid Option for 57 Year Old Patient with Recurrent TaLG Tumors, Small Size, Negative Cytology?

  Sunday, May 15, 2022
  2:05 PM – 2:25 PM